Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Radoslav Mladenov

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Immunology and Cell Biology|January 9, 2016
Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophagesDmitrij Hristodorov, Radoslav Mladenov, Rainer Fischer, et al.
Toxins|October 30, 2012
Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseasesDmitrij Hristodorov, Radoslav Mladenov, Michael Huhn, et al.
Mabs|December 18, 2014
Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapyDmitrij Hristodorov, Radoslav Mladenov, Hannes Brehm, et al.
British Journal of Haematology|October 30, 2013
Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivoDmitrij Hristodorov, Johannes Nordlohne, Radoslav Mladenov, et al.
Mabs|July 29, 2015
Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsiesDmitrij Hristodorov, Radoslav Mladenov, Verena von Felbert, et al.
Biomedicines|June 28, 2017
Human MAP Tau Based Targeted Cytolytic Fusion ProteinsOlusiji A Akinrinmade, Sandra Jordaan, Dmitrij Hristodorov, et al.
Cancer Letters|April 19, 2015
Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion proteinHannes Brehm, Dmitrij Hristodorov, Alessa Pardo, et al.
Chemical Communications (Cambridge, England)|October 19, 2011
Asymmetric reduction of ketones with recombinant E. coli whole cells in neat substratesAndre Jakoblinnert, Radoslav Mladenov, Albert Paul, et al.
Cancer Letters|August 27, 2013
Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cellsSonja Schiffer, Soriba Letzian, Edgar Jost, et al.
Cancer Letters|July 13, 2014
A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissuesHannes Brehm, Judith Niesen, Radoslav Mladenov, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Immunology and Cell Biology|January 9, 2016
Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophagesDmitrij Hristodorov, Radoslav Mladenov, Rainer Fischer, et al.
Toxins|October 30, 2012
Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseasesDmitrij Hristodorov, Radoslav Mladenov, Michael Huhn, et al.
Mabs|December 18, 2014
Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapyDmitrij Hristodorov, Radoslav Mladenov, Hannes Brehm, et al.
British Journal of Haematology|October 30, 2013
Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivoDmitrij Hristodorov, Johannes Nordlohne, Radoslav Mladenov, et al.
Mabs|July 29, 2015
Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsiesDmitrij Hristodorov, Radoslav Mladenov, Verena von Felbert, et al.
Biomedicines|June 28, 2017
Human MAP Tau Based Targeted Cytolytic Fusion ProteinsOlusiji A Akinrinmade, Sandra Jordaan, Dmitrij Hristodorov, et al.
Cancer Letters|April 19, 2015
Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion proteinHannes Brehm, Dmitrij Hristodorov, Alessa Pardo, et al.
Chemical Communications (Cambridge, England)|October 19, 2011
Asymmetric reduction of ketones with recombinant E. coli whole cells in neat substratesAndre Jakoblinnert, Radoslav Mladenov, Albert Paul, et al.
Cancer Letters|August 27, 2013
Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cellsSonja Schiffer, Soriba Letzian, Edgar Jost, et al.
Cancer Letters|July 13, 2014
A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissuesHannes Brehm, Judith Niesen, Radoslav Mladenov, et al.
Pageof 2